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ABSTRACT

An a ste rosaponin extracted £rom. the Atlantic starfish _A. ste r~~
forbesi (Desor) has teen evaluated for pharmacological activity.
The investigation has revealed that while the asterosaponin does
not exi1ibit all the activities that would be expected, such as hernotoxicity to blood cells, choline rgic blocking activity, initiation 0£
a.voidance .i.'ebEJOnse reaction or production of autotomy, it does exhibit soLJ.e unique propert: ,o: s not demonstrated by other a sterosaponins.

These activities include an z. lgesia, anti-inflarnrna tion, a.nd

transient hypotension produced by a direct effect on the vascular
bed.
The bovine serum albumin assa.y Jor anti-in£lamrnatory activity
showed that a concentration of 500 µg/rnl of asterosaponin caused
an 85% inhibition 0£ protein denaturation.

The rat paw edema assay

demonstrated that pretreatment with asterosaponin at 75 mg/kg ip
significantiy reJuced the edema caused by the ca rrageenin injection.
In both cases the response was dose dependent.
The analgesic activity of the asterosaponj.n was analyzed using
the Koster acetic acid writhing test.

Significant analgesia was dem-

onstrated with a dose of asterosapcrnin

2.s

low as 15 mg/kg while

25 mg/kg was capable of r educing the writhes by 99%.

i

The transient hypotensive activity of the asterosaponin was
demonstrated in rats, cats, and dogs.

Utilizing the cat it was dem-

onstrated that very low doses of the asterosaponin (0. 5 mg/kg) could
significantly transiently lower the blood pressure, but had no effect
on the nictitating membrane or on somatic muscle contra ction.
The rat was less sensitive to the intravenously administered asterosaponin then Lhe cat, eliciting a hypot e nsive effect only when concentrations oi 4 . 0 rng/kg or higher were administered.
of the d og to asterosaponin was intermedia t e .

The sensitivity

The dog exhibi.te d

a drop in blood pr essu re when a dose of 2. 0 mg/kg of asterosaponin
was adn1inistered, and similar to the cat and rat showed a dose
response relation ship

~o

the asteros aponin.

The rnechanisrn by which the asterosaponin caused the transi ent
d1·op in blood pressure was investigated by an analy sis of vagal
influence, the possibility of histamine release, direct action on the
vasculature and th e possible complex involvement of some type
of adrenergic blockade or stimulation using an experimental set up
rnonitoring blood pressure, heart rate and ECG.

The data showed

that th e asterosaponin continued to exhibit its hyp otens ive ac tion
even when the vagus nerves were severed, the animai was pretreated with antihistarnine, the a l pha recepto rs were blocked, or when
th e b eta receptors wer e bi.ocked.

l l

The hind leg perfusion experim.ent perfonned on the rat proved
that the asterosaponin was acting directly on the vasculature.

The

experiment showed that the asterosaponin was capable of causing
vasodilation directly when all neural influences were removed by
cervical dislocation and severing, and was even capable of acting
in the presence of beta blockade created by the administration of
propranolol to levels which blocked isoproterenol effects.
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I.

INTRODUCTION

The phannacological evaluation of comp oun ds extracted from
plant or animal sources is basic to the science of pharmacology.
The employment of animals and plants from the marine environment
as a. soucce for biologically active compounds has created the field
of n.1.arine ph2.rrnacology.
The isolation of toxic saponin cornpounds from starfish in the
ea.rly 1960s (Hashimoto and Yasumoto, 1960) ren ewe d the scien tifi c
argument as to whether starfish e1nploy some type of toxin in order
to facilitate prey procurement, specifically the opening of the bivalve shell.

Further res e arch into the phannacological properties

of these asterosaponin corn.pounds (Rio et al., 1963; Yasurnoto -~!
al., 1964; Rio et al., 1965; Yasurnoto et al., 1966; Friess~ al.,
1968; Friess, 1970; Shimizu, 1971, 1972) indicated that the asterosaponins were not a toxin used by the starfish to aid in the opening of
bivalves but that these and related ccrnpounds did possess many
pharmacological properties.

These properties included activity as

antiviral agents (Shimizu, 1971), anticoagulant a.gents (Baslow, 1969),
cytotoxins (Ruggi er i, 1965), reducers of sperm motility (Ruggi er i,
1965), choline rgic blocking agents (F' rie ss, 1970), hemotoxic agents

8

(Owellen et al., 1973), producers of an avoidance response reaction

by mollusks (Mackie et al. , 1968) and antifungal agents (Wolters, 1968).
Dr. Yuzuru Shimizu isolated an antiviral asterosaponin extract
fro1n the .A.tlantic starfish Asterias forbesi in 1971.

This astero-

saponin (Figure 1) is an aglycone with a sulfate group and sugars
attached ,

That structure is characteristic of saponin cornpounds

derived from starfish and is very similar to compounds extracted
from I-Iolothurins (Friess et al., 1965; Friess and Durant, 1965).
The investigation of the pharmacological properties of this purified
and identified asterosaponin from
for this thesis.

~-ster~as

£9rbesi was the basis

The investigation was aimed at evaluating the astero-

saponin for pharn1acological activities that had be e n exhibited by
other asterosaponin or related compounds.

The investigatorfl were

a l so interested in evaluating the extract for properties not previously
associated with a&terosaponins and to determine the mechanism

by which these activities we re produced in the hope that the compound
rnight exhibit activities that would be cf use as either a research
tool or a possible drug.

9

FIGUR E 1.

0
SULFATE

ST RUCTUR E O F AS T EROSAPO N I N
FROM ASTERIAS FOR B ESI

0 (SUGARS)

n

FU COSE
QUINOVO SE
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II.

LITERATURE REVIEW

Nigrelli (1952) isolat e d the first saponin of animal origin when
he isolated the compound he later called Lolothurin from a sea
cucumber.

The Holothurian from which the saponin was isolated

is a rnernb e r of Lhe phylum Echinodermata as are the Asteroidea
or star.fish.

Hu!othurin was shown to exhibit toxic effects on th e

killiii sh c:,nd pea. rl fish, and the compound restricted the growth of
sarcoma 180 in Swiss Webster mice.

I'·J igrelli

~al.

(1955) reported

on the che1nical nature of this compound from the Holothur i an and
showed that this toxic compound had a steroid nucleus and a r:r1onosacchar ide moiety.

Sulliva n

et~·

(1955) demonstrated that the

compound had anti-tumor activity on the Kr eb s - 2 Ascites Tumors
in Swiss mice.

The investigation of the pharm a col og ic properties

of this toxin was c o ntinued w ith the work of F1:iess et al.

(1959)

who demonstrated that the tox in had irreversible blocking effects
on the rat phrenic Eerve-diaphrarn preparation.
w·ork cmcerning holothurin cmtinued into the 1960 s v.1 hen Frie SS
and Durant (1965) and

Fri e ss~

al. (1965) demonstrated that the anti -

cholin ergi c activity of t h e toxin demonstrated through the rat phr eni c
nerve experiments cculd be partially blocked by physostigmine and
neostigmine.

11

Saponins from other animals were discovered in the early 1960s
when Matsuno and Yamanouchi (1961) isolated a saponin from a different Holothurian then the one Nigrell:i had used.

This was done

while the choline rgic involvement of toxic substances fron1 echino derms beca1ne even more well docu1nented through the work of Mendes
et ~l. (1963).
The isolation of toxic principles from the Echinodern1ata rekindled the long fought argument over the possible presence of some
type of toxic substance in starfish which is used by the starfish to
facilitate food procure1nent, specifically a toxin that would reduce
the effort necessary for the sta.rfish to open the bivalve shdl.
The toxic substance investigated by this research was isolated
from the Atlantic starfish Asterias forbesi and was tested on one of
the starfish's comrnon food sources, the quahog Mercenaria rnercenaria. Thus the literature dealing with possible toxins possessed by
starfish has focused on this particular starfish, ancl when possible
in relation to the clam Mercenaria mercenaria.
The first hint of evidence for or against a toxin being used by
the starfish Asteri;:is fo r besi con1es fro:m the work •:)f Galtsoff and
Loosanoff (1939). · While inv estigating the problcrr; of Asterias
forbesi plundering the oyster a.nd clam beds of the eastern shore
they observed that, on occasion, specimens of Aste rias would be

12

unable to open large r.ciollusks and would leave the mollusk and go on .
The conclusion could be made that if a toxin were present in the
starfish, it would be unlikely for this response to be necessary.
Further evidence against the presence of a toxic substance used by
Asterias forbesi in food procurement has been presented by the
work of Burnett (19 55, 1960).
J.?._E.~~esi

a toxin

Burnett showed that for Asteria s

the:ce have been no evolutionary pressures to develop such
beca1:Lsr~

'.:he starfish is .fully capable of exerting a force grea.t-

er than 5, 500 grams, a full l, 000 grams greater then the force
needed to open a quahog.

Burnett demonstrated that the sta dish

does not pull on the shell of the quahog continuously and that the shell
halves w ill frequently snap shut on the everted stomach, with no
noticable adverse eHects to the starfish.

(1960) showed, using

Aste.E_~as

Furthermore, Burnett

forbesi and Mercenaria mercenaria

that the ston1ach of the starfish could pass through very small openings in the clan1 and that th0. starfish contained stomach enzymes
capable of digesting the living clam.

Burnett concluded (1960) that

t!Thus, there is strong e vidence that Asterias secretes no poison
before it begins to digest a clam. 111

1
A. Burnett, 11 The rnechanisrn ernployed by the starfish Asterjas
forbesi to gain access to the interior of the bivalve, Venus mercenaria,
Eculogy ±l_ (1960): 584 .

11
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Lavoie (1956) presented additional evidence that starfish e1nploy
no toxic compound in their acquisition of food by using extracts of
Asterias i_orbesi on the rn.ussel Mytilus edulis.

Various extracts

from the stornach and pyloric caeca were tested by a nw:nbe.r of techniques.

The extracts were tested by injection into the rnantle cavity

of the mussel, by injection into the adductor rnuscles, by addition
to the sea water containing tile mussel and the extract was even
per£uf>ed on the expo sed heart of the Mytilus.

All of the experiments ·

·with all the ext racts produced the san1 e results; there was no difference in the effect seen with the starfish extract from the response
seen with sea water used as a control.

Lavoie aiso de1nonstrated

that the starfish could enter the clam through a gap as small as
0. 1 nun.
'

1

However, the conclusion that was made by Lavoie was that,

The negative results of the experin1ents involv ing sea star extracts

are not proof that asteroids do not secrete a toxin during predation,
but they do indicate that no such substance can be separated from the
sea star organs by the extraction methods used.

112

The conclusion

It is irnpossible

indicates the dilemma these investigators face.

to prove that a toxin does not exist, and only possible to prove that
one does exist when it is derr10nstrated un e quivocally.

This has

not be en done.

2,"
L _ .
, 1i:..:r
lvl..
. a-vo1e,
Low sea ::;tars open bivalv e s ,
(195 6 ): 122 .

11

Biol. Bull. 111

14

Christensen (1957) also supported the mechanical theory of
starfish access to mollusks, that is, that force was the

11

primary 11

method employed by seastars of the Asterias type to gain access to
the tis sue of the bivalve prey.

The hesitance on the pa rt of the

researcher to completely dispel the idea of a toxin being present

is evidenced here by the choice of the word

11

primary 11 •

Nichols (1964) continues to include the idea that a toxic substance is b eing used by starfish in prey predation, anC. Aldrich presents observational data (Aldrich, 195 4 ) in his Ph.D. dissertat .ion
that extracts from Aste rias fo
of the add uctor muscles
plicata.

r;f

r~e

si_ do indeed produce relaxation

]yiytilus edulis and 11odiolus demissus

Aldrich 1 s data however i_s based on observations of the

response of Mod_i.olus demissus to extracts of Asterias tissue where
a gaping response was interpreted as being the result of a toxic
substanc e present in extracts from. pyloric divertic;ilun-i.

Unfor-

tun.ately no reason was given by Aldrich as to why the response
of Modiolus was inconsistant.

With both the filtered and dialized

extracts there appears to hav e been specimens which were not affected by the extract.

Observations of an Asterias feeding on a

Mytilus edulis is the second source for Aldrich 1 s belief that the
starfish contains a toxin.

The fact that the starfish stomach is evert-·

ed at the begining of the attack supposedly suggests the role of a
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chemical rnediator prior to the mechanical phase of penetration.
Hashimoto and Yasumoto (1960) in studying an extract from the
starfish Asterjna pectinifera which had been shown to b e toxic to
oyster hearts, could hinder the ecdysis of fly maggots, and was
toxic to fish and warm blooded animals, noticed that the water in the
aquarium which held the starfish oft en turn ed foamy when starfish
died.

I--lypotbes.izing that the extract that th ey had been studying might

be respcnsihJe for this foaming, and knowing that one of the properties of saponins is their surfactant nature, they initiated a search
for a saponin compound in the starfish.

Inde ed , when isolation

procedures were completed the compound was classifi e d as a saponin.
Continuing their work Yasurnoto a nd Hashimoto, together with
Watanabe (Yasumoto et al., 1964) s h owe d that w ith better extraction
proc edures u sing the starfish Asterias amurensis a highly purified
toxic saponin fraction could be obta ined.

This new asterosaponin

proved to be hemolytic to rabbit blood and toxic to killifish, earthworms and fly maggots.

When 80 rng of the starfish saponin was

injected into the mantle cavity of three individual oysters through
a hole in the edge of their shells, these shell fish, which were kept
in an aquarium, showed no signs of relaxation of the adductor muscles
for the six hour observation time.
These resul ts of Yasumoto ~__! ~· (1964) sugges t that the aste rosapo nin is not

1

esponsible .for facilitating the starfish 1 s ability to
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open the clam or oyster, but that it may be present for another
purpose as y e t obscure.

This corresponds with the opinion of F e der

and Christensen (1966) who beli eve that there is no basis for the
toxin theory.

Howe'7er th ey do believe toxic substances a re pr e s e nt

in starfish, but that th ey are not utilized for prey procurement.
Yasumoto ~ ~·

(1966) investig ated whether starfish in general

possess saponins since saponins had b een believed to be r est rict ed
to the plant kiDg dom prior to the work of Nigrelli.

Analyzing five

different starfish speci es , th ey found that all the s tarfish analyzed
did contain saponins.

The saponins we re found in a ll parts of the

starfish body and were at high es t concentrations in the summer
rnonths.
Rio et a l. (1 963) in Nigrelli 1s laboratory detennined tha.t th e
giant sunburst starfish Pycnopodia helianthoides from the Pacific
n orth west also pos se ss ed a saponin, and tha t t his asterosaponin
differed from the Holothurian saponin.

The compo und was cytoto x ic

and h emo lytic and contained a steroida l aglycone characteristic
of the s a ponins.
A toxic extra ct from Asterias £orbesi was demonstrated by
Chaet in 1962.

He showed that the scalded coeleo1nic fluid of Astei- i as

contained a toxi n which when injected into the peritoneal cavity of the
s tarfis h Asterias

£or1~~si

ca'...ised autoto1ny (the rejection of the star-

fish1s own arms) 2. nd death.

Toxic fractions from other species
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of Asteria s we re examined by Fange (1963) who showed that an
extract from Asterias _E21bens produced the irreversible contraction
o.f the isolated Buccinum radula muscle.

This fraction was inactiv-

ated by b o iling .
Rio et al. (1965) evaluated the biological activities of extracts
from five starfish species .

Althoug h one of the asterosaponins eva l-

uated was extracted from Aste rias forbesi, it is not believed th at
the c ornpon nd is t he same as the compound isolated by Shimizu.
No structure for the compound was determined, but the extraction
procedures are n ot the same.

The Aste rias for be si toxin was shown

to be toxic t o Fundulus heteroclitus down to a level of 2 pg/ml.
However, no mark e d eosrnophil.ia or hernolytic activity was reported
for the compound.

The compo1-md was shown to imrnoboli z e sperm

and cytolyz e unfertilized sea urchins eggs.
Friess, Durant and Chanley (1968) used i.he rat phrenic nervediaphram preparation on two saponins from the starfish Asterias
amurensis to evaluate the cholinergic properties of the asterosaponins
as they had done for the holothurin in 1959.

Their work established

that these two saponins demonstrated irreversible block ade of contractural responses elicite d b oth directly and indirectly.
In 1970 Friess reviewed the literature o n the steroidal sap on in

esters £::om Echinoderms (Fri ess , 1970 ).

The c ompounds investigat ed

were ±:rom s ea cucumbers and starfish and all contained the steroidal
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nucleus, polysaccharide moiety and esterified sulfuric acid residue,
w hile some of the sugars present on the moiety included D-quinovose
and D-fu cose.
ure ~sis

Refering to the work 0£ Hashimoto on Asterias am -

Friess pointed o ut that both asterosa p onins A and B extracted

from the starfish contained the same aglyco n es and one sulfate group .
Th e sulfate group was suggested to be the part of th e compound
re sponsible fur tD.e toxicity and anionic character.
co'1.tained only

tl~e

Comp ound A

terminally reduced sugars fucose and quinovose

but both asterosaponin A and B were

11

quite'' powerful in destruction

of excitability of a cholinergic neuromuscular preparation.
Shimi zu in 1971 iso l ated an anti-viral substance from the starfish Asterias forbesi (Shimizu, 1971) .

This compound later (Shimizu,

1972) was established to be of the class.ical steroidal aglycone, polysac cha ride moiety and sulfate derivative form, and is the compound
that was used in this investigation.
Mentio n has already been made to the possibility of an avoidance
respons e reaction being caused by the asterosaponin.

The work of

Fange (19 63 ) Feder and L asker (1964) Feder and Arvidsson (1967)
and Mackie et al. (1968) clearly shows that extracts from starfi sh
could initiate an escape response in rnollusks .

The observations

of Pratt and Campbell (195 6 ) suggested that the mollusk Me rcenaria
mercenaria n1ay be able to sense the presence of Asterias forbesi
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and initiate an avoidance or escape response.

These beliefs were

based on the observation that quahogs appear to burrow deeper when
Asterias are in the vicinity of the bivalves.
Ast e rias forbesi often feeds on 1.:he clan1 Mercenaria mercenaria.
There is evidence that asterosaponins can be cardioactive (Hashimoto
and Yasumoto, 1960) and this is another side to the debate as to
.,,-_,he~.he;_·

the sta riis h opens the bivalve with shear force or through

ihe use of a toxie.

In order to facilitate an evaluation of the bivalve

toxicity, and the cardioactive and cholinergic properties of the asterosaponin b ackgrcund information on the anatomy and physiology of
!~e!cenaria rn e rc 811~ri a ,

to was necessary.

its heart, and the chemicals it is sensjtive

This informat ion has be en given by Prosser

(1940), Gre enberg and J ega l (1963), Greenberg (1965), Florey (1967)
and Agar wa l and Greenberg (1969).
Advancing the research covered by this thesis into activities
of asterosaponins not already cited as being properties of asterosaponins it was decided to investigate the possibility of anti-inflam-·
lnatory activity, analgesic activity, and the effects of the asterosaponin on the rnammalian cardiovascular systern.

Reviewing the

literature on anti-inflammatory assay procedures it was determined
to us e th e procedures of Grant

~J.

al. (1970) fo.:.· the in vitro assay

and that of Winter et a l. (1963) and Winter

anc~

Flataker (19 65 ) for
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the in vivo method.

The procedure of

Koster~

al. (1959) was

reviewed and chosen to be used to evaluate the analgesic activity
of the asterosaponin.
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III.

A.

EXPERIMENTAL

Animals
Male albino rats we i ghing between 150 to 500 grams and male

mice, 30 to 50 grams (Charles River Breeding Labor atories, Wilm.ingto11, 1v1ass3chuestts) were used.
10

The animals were housed

quar tel"s JY1aintained at 21-23°C with room lights on alternating

12 hour ligh t-dark cycles.
were allowed ad libitum.

Corn.rnercial laboratory chow and water
Anirnals we.::e used no ear li er than three

days foUow5ng receipt frorn the supplier.
Cats and dogs from. the University of Rhode Island College of
Pharmacy 1 s kennel were of mixed breed.
Clams,

Mer~~_?aria

mercenaria, were obtained from Wickford

Shell Fish Inc. (Wickford , Rhode Island).

The clams were stored

in aerated artificial sea water aquaria (Aquarium Systems, Inc.,
Cleveland, Ohio).

The temperature of the sea water was rnaintained

at 15-20°C with room lights on alternating 12 hour light-d ark cycles"
The starfish (Asterias forbesi) that were us ed for the extraction
procedure and for experimentation were collected from Narragansett
Bay in the shallow areas (usually at low tide) off the rocks close
to Hazzard Ave. in Narragansett, Rhode Island .
The snail

L ittor~E_~

_!_itt o r ea was collected on the rocky shore

2, 2

of Narragansett Bay at lo w tide near the ''Towers" of Narragansett,
R.hode Island.
B.

Materials
Analytical grade chemicals or equivalent were used throughout

the study.

Carrageenin was obtained from Marine Colloids, (Rock-

land, Maine).
Two sc.n:pJ.i:, 5 of ast erosaponin were used in this investigation.
The origi1ia1. extract , produced by Dr. Yuzuru Shimizu of the Department of Pharmacognosy of the University of R.hode Island was only
occasionaly used in the investigation as indicated.

The major por-

ti.on of the research was carried ou_t on ::Da.teri2.l that was extracted
and purified by Les Goldsrnith duri n g the Sl.L.'"Y1mer of 1973 under the
guidance of Dr. Yuzuru Shimizu.
C.

Analytical Procedur e s
The asterosaponin was dissolved in 0. 9% saline for intravenous

and intraperitoneal administration, artificial sea water for marine
preparations, distilled water for in vitro preparations and RingerLocke solut:i o n for hind l eg perfusion preparations.

The asterosaponin

was often used in doses of l. 5 x 10-powerg/ml because the estimated
molecular weight of the compound was l, 500 (Shimizu, 1972) thus
allowing for easy conversion to rnolar concentration.
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1.

Cholinergic Assay and the Effects of Asterosaponin on the Mercenaria mercenaria Heart
Large bivalves 1'.1ercenaria rn.ercen2.ria were kept in aerated

artificial sea "''ater 15-20°C until u.scd.
out under sea water.

The dissection was carried

A bivalve specimen was selected ci.nd the edge

of the shell taped until a small crack appeared.

The clam was then

opened by cutting the adductor inuscles, and care was taken not to
injure the portic)n of the clam close to the hinge, as this was the
vicinity of the heart.

After removal of extraneous tis sue, the dorsal

half of the clam_ was transfered into the dissection dish with the
dorsal side (containing the heart) up and a superficial sagital cut
was made along the dorsal body wall.

The heart was then isolated

and prepared for removal by cutting the intestine which passed through
the heart on both sides.

Ligatures were tied around both ends of the

ventricle, so that eventually one could be attached to a transducer
and the other to a glass hook.

The heart was severed distal to both

lig atures and immediately transfered to a 10 ml muscle bath with a
surrounding jacket through which cooled (18°C) wate1· was purnped
to regulate the temperatur e of the heart and solutions.

A constant

but gentle stream of air bubbles continualJ.y oxygenated the bea rt
preparation.

The heart was held in the bath with one ligature connect-

ed to a glass hook at the

botton~

of the bath while the other li gature

was connected to the A-715 transducer attached to a Physiograph
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(E. M. Instrument Co., Houston, Texas).
Standard dilutions were nl.ade of acetylcholine in sea water
to cover a range of 1. 0 x 10

-4

g/ml to 1. 0 x 10

-12

g/ml.

One ml was

added to 9 ml of sea \vater to reduce th e concentration by 1 power
of 10.

The effect of the acetylcholine, or test drug was recorded

for 30 seconds and then the heart was flushed two times with sea
water and a il o'>ve d to stabilize for o ne rninute or longer.
·'

with the l. 0 x 10 --

12

Startin g

g/ml concentration of acetylcholine, the concen-

tration was increased until the h ea rt beat stopped. ·Interme diate
concentrations between th e le ve l of acetylcholine that conl.pletely
stopp ed t:b.e contractions and the next more dilute concentration
we1·e occasionally appli ed to exceptionally sensitive hearts to attain
a finer comparison of activity.
The acetylcholine effect was then compared to the effect of
different concentrations of the asterosaponin, following the same
procedure.

Sarnpl e s of acetylcholine, giving known activity were

administered intermittently to the test preparation during asterosaponin testing to rnonitor the deterioration of the sensitivity of the
preparation.

The anticholinesterase neostigmine and the antichol-

inergic atropine were used to gain more info rmation £ro1n the preparation.
2.

Effect of Asterosaponin on the 'Whol e Clam Mercenariamercenaria
Fiv e lar ge bivalves 1v1ercenaria mercenaria had s1nall hol es
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drilled in the ventral lateral section of their shell so that a small
syringe needle could be inserted into the mantle cavity of the clam.
4
Four of the clams were injected with l rnl of 1. 5 x l0- g/rn_l asterosaponin while the fifth received a 1 rnl injection of sea water.

The

c lams were all placed in a container of aerated sea water for 24
hours and observed for any type of reaction to the experimental
pl'ocedure .

Expe rim en ts designed after the experiments of Mackie et al.
(1968), were performed to determine if there were any escape response reactions 0£ the local salt water species of gastropod, _Littorina littorea to the asterosaponin.
The snails were placed in individual beakers of sea water that
were positioned over pieces of graph paper.

When nonna1 explor-

atory activity of the snail had resurned, the asterosaponin was gently
injected into th e sea water close to the head of the snail with a syringe.
T h e response of the snail was then recorded, using the graph paper
squares to det e rmine the movement of the snail.

Injections of sea

water via syringe into the snail 1 s sea water environment at the pr ox-in1ity of his head were used as a control.

A different snail was used

for each dose of asterosaponin tested.

The following procedure \Vas used to determ ine if the Asterias
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forbesi asterosaponin exhibited blood cell lysing properties similar
to other asterosaponins.

Rat blood obtained from tail veins was

treated with concentrations of asterosaponin ranging from 0. 3 to

10. 0 mg/nil, or witli the st3.ndard lvierck saponin used for blood
count deterrni:;.1ations.

The bloo<l san1ples were placed in a Coulter

Counter and the blood count determined.

Chact in i9(;2 had dernonstrated the ability of a co1npound from
the sea lded coe lornic fluid of Asteria s forbesi to bring forth an au tonoewus loss of arms by that starfish, when the coin pound was injected
into its peritoneal cavity.

The procedure used in this

res~arch

to

investigate this property being possessed by the asterosaponin from
Asterias forb e si was
- - - - ·- - - - -

similar.

Intermediate sized starfish 8-12 crn in diarneter were injected
intraperitoneally with 1 ml of l. 5 x 10- 4 g/ml asterosaponin and then
placed in the aqua·riurn for observation.

Control starfish received

intraperitoneal injections of l ml of seav,1ater .

The starfish were

observed for .four hours and a bno nnal reactions were recorded.
The starfish were then observed periodically for the ne x t twenty
hours.

6.

Analg esia
Th e rnethod of Koster (1959) was the method used to evaluate

the analgesic properties of the &sterosaponi;-i.

Groups of 5 mice
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were pretr eated by ip injection with either; l) saline (0. 1 ml/g)
2) morphine (10 mg/kg) or 3) asterosaponin.

The asterosaponin

was dissolv ed in saline and was adrninis terpd at 6 dosage levels
ranging from 10 mg/kg to 50 mg/kg .

Fifteen minutes after the pre-

treatment :injections the mice received ip injections of 0. 01 ml/g
of 0. 6% fresh acetic aci d .

Three minutes after the acetic acid injec-

tions the w ri thes exhibited by the group of mice were counted and
to~aled

fo _r twelve minutes.

In this procedure reduction in w ri thes

is equated with analgesia.
7. _In Vitro Anti-inflammatory

As~

To evaluate possible anti-inflarnmatory activity by the a ste ro<::aponin the in vitro assay of

Grant~

al. (1970) was e1nployed.

The assay en1ploys the use of bovine serum albumin.

Many corn -

poun ds that prevent inflarnmation also are capable of reducing ti1e
heat denaturation of a l.bumin protein.
Th e test system contained 2 rr1l of

1%

bovine serurn albumin and

2 ml of 0. 05 M Tris acetate buffer, pH 6. 0 or test solution in
te st tube.

2.

Cont ro l and test systems were heated in a constci.nt temper-

atur e bath using the Haake FK2 ccnstant tem.perature circulator
at 69. 5°C for exactly four rninutes.

The test tubes we re th en placed

in ic e and their turbidities were read <'. t 660 mr1 on a Beckman model
DB-G spectrophotometer.

If the original turbidity was above scale,

th e sam.ple was dilluted 9: 1 with

distill~d

water.

The value of the
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percent of control turbidity was calculated and an analysis of variance calculated to determine if ther was a significant drug effect .
8.

In Vivo Anti-in£laE1'1-mato ry As sa_y
Since positive results obtained from _?-_r: vitro anti-infiammato ry

assays are inconclusive in deterrr1ining the presence of anti-inflammatory activity for a compound, the in vivo anti-inflammatory pro-

cedure of Winter et al. {1963) was also ernployed.

Rats weig hing

approxi:nat e ly E;o g received either no pre-t .r eatxnent, asterosaponin
75 mg/kg ip or phenylbr:.tazor:>e 90 mg/kg ip, one hour p~·ior tn ec.leCJ.1<:
productic

1.

1

:=:dema was produced by the

inj<~cti.or:

of 0. 05 ml of 1%

c:a:crageenin into the sub-plan"Ler tissuE' of a hix::6 pa -;;,· of a r at .

Th<~

vo lurne of the paw was then innnecli.ately deterrni:--ied by the use of
a prcviousiy calibrated volume dii:~pla cern_e nt apparatus which employ-

ed the use of a 50 ml syringe iilled with mercury corn:!ecte;d th rough

a p l astic

catb. ·.~ter

tc. a :St2.Lharr-1 P

The tcxi.ci ty oi !:he
of 5 rna.le mice

-~'/ e:re

;~3

transducer iink ed to a Grass

asten:' sa:pc~1_i_J:l

was evaluated in mice.

Groups

i:;jccted i r:d:r<.1.peritcnc:ally w.ith 5-0 , 100, 2.00,

or 400 r_ng/kg oi L:ic: :J.sterosaponin.
The

respo~1s:::

of tbe mic:e to tlu· int raper itoneal asteroaaponin

injection \'vas obse r ved for t wo h ou.1·s aod
vatir__:.ns we · e m<.;.;c; c·ver the ne>..t

thn~e

~:hen

d'1y::>.

intermittant obser-

Thi= number of deaths
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were recorded and an LD50 estimated from the results.

10.

Cat Blood Pres sure and Nervous System Evaluation
The effect of the asterosaponin on blL)Od pressure, respiration,

the autonon1ic nervous systen1, and skeletal in us cle re spans e to
neuronal. stin1ulation were determined using a cat.
A cat was anesthetized wi.th pentobarbital.

The cat's respiration

'Nas mon[tored by the use of a sensitive thermocouple inserted into

the plabtic cannula used in the tracheoton1y.

The thermocoupl e

was then connected to the Grass polygraph via a Grass model 7PlB
low level D. C. pre-amplifi er aD.d a model 7DAE Grass polygraph

D. C. driver amplifier.

Blood pressure was monitored using the

cannula.tion of the femoral artery connected to the same Gr.ass polygraph and amplifier system by a 1nodel P 23 De 10 volt Statham
transduc er .

The effect of stimulating the nictitating membrane

was also record ed on the polygraph.

The nictita ting men1brane

response was tested via supramaximal stirr1ulation (7 volts, 5 per
second for 2. 0 milliseconds) of the cut preganglionic cervical syrnpathetic nerve .

The response of a striated rnuscle (tibial.is anterior)

to supramaximal stimulation (10 volts, 1 per second for 2. 0 inillis econds) of the p e riph e ral end of the cut peroneal nerve was also
monitored.

The tibialis anterior and the nictitating membrane were

connected to a Grass force displ a c emen t transducer model

~T

connected to the polygr a ph to r ecord contractions of the muscle

03C
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or membrane.
The effects of the asterosaponin on the monitored parameters
were eva l uated after intravenous administr ati on of the canpound.
Vfhenever th e asterosaponin or other drug was administered the cannula was immediately flushed with saline.
/

11.

Blood Pressure and ECG Resoo nses of the Rat to Ast erosaoonin
------------·
--The response of the cat to asterosaponin adrninistration initiated

interest into the cardiovascular effec t s of the asterosaponin.

These

cardiovascular effects of intrav enous asterosaponin achninistration
were further investi gated primarily in the rat.
A rat was anestheti7-ed with ur ethane (6 rn.l/kg of 20% solution,
i p).

A tracheal cannula (a 1. 5 11 piece of PE tubing , size 280 or

smaller) was then inserted and tied securely.

The femoral vein,

as it passed into the iliac vein was exposed and cannulated with PE

10 tubing and conn ec ted to a l ml syringe that was filled with saline.
This cannula was used for intravenous drug ad1ninistration.

Each

of the con1mon carotids were exposed and separated from the surrounding tissues .

Then the two nerves, the vagus and the cervical syrn -

pathetic which lie along the carotids, were carefully and gently
separated from the section of the vesse l to be us ed for blood pressure
catherterization usin g PE 90 tubing.

Prior to its insertion the cannula

was attached to the saline filled transducer system in the 1.isual .
rn.ann er and the tip filled with heparin solution.

A blood pr e ssure
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bottle filled with 250 ml of saline and 2. 5 ml of heparin (1000 units /ml)
had been previously attached to this transducer.

This system was

used to re co rd the blood pressure changes following drug adminis tration .
To record the rat 1 s ECG three needle electrodes were placed
subcutaneously.

The ground electrode was connected to the leg of

th1:: rat that v: 2, s not used for the intra7enous catheterization.

The

two ren1a i njng electrodes were placed on the .chest of the rat or
on his outstreached forepaws.

The electl"odes were connected to the

Grass polygraph wide band A. C. pre-amplifier and integrator model

7 P3A which was connected to the Grass polygraph D. C. Driver
arnplifier inodel 7 Di',E .

The paper speed was kept at 2. 5 mm/sec.

except for recording at critical times at 100 inm/second.
12.

Dog Blood Pressure, Heart Hate, and ECG in Response to
Asteros a ponin
T he experimental set up to monitor the effects of the astero-

sapo.nin on the blood pressure, heart rate, and ECG of the dog was
sirnilar to that of the rat.

The dog was anesthetized with pentobarb-

ital 30 mg/kg and a tracheotomy performed.

The f e moral vein was

cannulated on one leg of the dog for the ad1ninistration of drug i'1travenously .

The femoral artery on the other l eg was cannulc<.ted and

attacheci to a pr essure transducer for the r eco rdin g of the arterial
blood pressure through a Grass polygraph.

The ECG recording
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responses to the vagus.
In a s e cond part 0£ the experiment, asterosaponin was adn1inistered after the vagus nerves had been severed, and the results
recorded to compare them to the normal effects of the asterosaponin
or; a rat with intact vagus nerves.
14.

Evaluation of the Histamine ReleasiE_g Potential of A stero saponin
The prJssibility that the hypotensive effect seen with the astero-

sapo nin adrnini8 tration could be caused by endogenous histamin e release was evaluated.

Rats were prepared for ECG monitoring and

blood pres s ure determination.

The antihistamine diphenhydran1ine

w.a s adrninistered intravenous ly to the r a t until su££icient amounts
were present to prevent the hypotensive activity of intravenously
adrninistered histamine (0. 5 mg/kg).

When a protective level of

antihistamine was attained asterosaponin (15 mg/kg) was administered
intravenously to d eter rr1ine ii th e hyp oten sive action of the asterosaponin could be blocked by pr etreatment with the antihistamine.
15 .

Evaluati o n of the Alpha Adrenergic Blocking Capabilities of
}\ ste ros_aponin
An analysis of the in£luence of the asterosaponin on the alpha

receptors of the adrenergi.c nervous system was possibl e from the
cat nictitating membrane exp e riment.

To gain more direct eviden ce

for the possibility of this type of activity, a specific experirnent was
designed, incorpor2.ting the rat blood pr e ssure pr eparation .
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Rats were prepared for the usual ECG and blood pressure
d eterminations.

Phenoxybenzamine was then administered to the

rat to the point where no further drop in blood pressure was seen.
Then asterosaponin (15 rng/kg) was adrninistered intravenously to
deterrnine if the asterosaponin could produce further hypotension
even th ough the alpha receptors we re blocked.

The normal proce -

<lu re of flushing each dose of a.dministe red drug with saline before
the next drug was administered was maintained and ample tirne
was a.llowed for each drug to have an effect.
16.

Evaluation of Beta S!imulating Properties of .Asterosaponin
The stirnulation of the vascular beta receptors by adrenergic

agonists can significantly alter peripheral resistance.

The stimu -

lation of these beta receptors leads to a drop in blood prei;)sure
through vasodilation.

The determination of the possibility of as-

terosaponin acting as a peripheral vascular beta stimulant was carried out using the rat blood pressure technique.

The possibility

of b eta influence was also inv est i gated with the rat hind leg perfusion experiment (see below).
A rat was pr e pared for blood p ressure and heart rat e rnonitoring

following the standard procedure for the blo od pressure and ECG
determi.'1.ation.

The beta. blocking agent propranolol was a.dminister--

ed intravenously to the rat a.t very high doses (O. 9 rng /kg), so that
no stimulation o f the beta receptors was possible.

After this blocking

35

dose had been administered, asterosaponin was injected and the
blood pressure measured to determine if the asterosaponin (15
mg/kg) could produce hypotension even though the beta receptors
were blocked.

17.

Evaluation of
!ur~.I.~_e

Asterosaponi~orking

Rat Hind

L~

Directly on the Vascula-

Perfusion Procedure

The results of the previous experirr1ents aimed at detenn]ning
the site of aste:rosaponin action in connection with the production
0£ transient hypotension made it necessary to further evaluate the

possibility that the asterosaponin was acting directly on the vasculature .

The perfused hind limb preparation makes this type of eval -

uation possible.
A rat was anesthetized and attached to a rat board that was

mounted on approximately a 50° angle so that the scrotal sac of the
rat was positioned at the lower end of the board.

The abdorninal

cavity was opened and the skin pulled away from the musculature
surrounding the scrotal sac and along one leg.

The vena cava and

decending aorta were carefully isolated below the level 0£ the kidney
and anterior to where they bifurcate into the lower app endage s.
The vena cava was tied just below the lev el of the kidney and the
aorta was cannulated.

The cannu la to the aorta was attached to

a three way stopcock permitting aerated body temperature RingerLockc solution t o be p erfused at a constant pressure into the artery.
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The stopcock could also be turned to allow for the administration
of drugs via a syringe.

The veins of the le g that had the skin pulled

away were severed so that the perfnsate could travel through the
arterioles and vascular bed and ernerge through these severed veins.
A small hole was plac ed at the bottom 0£ the scrotal sac and an eye
dropper insert ed therein so that the perfusate from the leg would
pass through t he eyedropper, dropping through a drop counter
connect ed to the polygraph.

Since the pressure was constant,

changes in the diameter of the vessels in the leg were reflected
in the num.ber of drops during a prescribed period of time.
Through the three way stopcock epinephrine (4. 0 pg) and isoproterenol (0. 1 mg) were administered to establish the reliability
of the preparation.

Standard amounts of Ringer-Locke solution

were also administered to evaluate the effect of the injection process
itself on the preparation.

Asterosaponin was adm inistered to record

its effects on vascular resistance.

Then the combination of adren-

ergic blocking and sti1nulating agents was used as a pretreatment
before the asterosaponin to verify the hypothesized rnechanism of
action of the asterosaponin.
D.

Statistical Methods
Th e 2-tail ed Student's

11

t 11 test for ind e pendent means was used

to exa1nine experirnental ineans for statistical significance.

The

level of significance (P) was detcrrnined b y compari son of the
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computed
ed

11

11

t

11

value with values from standard tables.

All calculat -

t 11 values were tested at the 0. 05 level for rejection of the null

hypothesis.

In sorne instances an analysis of variance, F test for

experimental means was used to examine experimental means for
statistical significance.

The level of significance (P) was determined

by comparison of the computed F value with value s from standard
tables.

All calculated F va lues were tested at the 0. 05 level for

rejection of the null hypothesis.
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IV.

A.

RESULTS

Me rcena ria. mercenaria Heart Evaluation for Choline rgic A ctivity by Asterosaponin
The clam_ heart bioassay established no activity by the astero-

saponin for the dose range of 1. 5 x lo- 18 g/ml (1. 0 x io-

7
-7
x 11)- g/ml (l. 0 x 10 M) (Table 1).

18

M) to 1. 5

The injection procedure, the

f reshness of the toxin, freshness of the preparation, and the order
of the administration of the drug had nc; effect on the results .
was den1onstra.ted in several ·ways.

This

The injection of artificial sea

water into the b a thing mediun1 producing no adverse effects showing
the injection procedure itself did not affect the contractions of the
isolated heart.

The order in which the different concentrations

of the drug were administered likewise did not alter the results
attained.

In some instances the lowest concentrations of asterosap-

onin were administered first, working progressively toward higher
concentrations.

On other occasions the experiment was initiated

using the middle concentration and at times using the highest concen tration of drug.

The possibility that the process of acetylcholine

ad1ninistration prior to asterosaponin pre ve nted the effects of the
asterosaponin was not seen.

Table l shmvs that the .!:"eliability of

the preparation was checked on every occasion for sensitivity to

TABLE l.

THE EFFECT OF ASTEROSAPONJN & ACETYLCHOLINE ON THE

____

CONTRACTIONS OF THE ISOLATED HEART OF M.E.RCEN.AIUA
. . .... MERCENARIA
~
·
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EXPLANATION OF TABLE 1

a This recording was r ecorde d as a slight drop.

However this was

probably due to the instability of the preparation since after sea
water replacen1ent the contractions were larg e r then with the toxin
for the first 3. 5 minutes but then the amplitude of the beat was com-·
parable to that exhibited with the toxin.
b

The dose of 1. 5 x 10

-7

g/ml was r e peated later in the expedment,

after trials with both to xin and acetylcholine, with the same effect.
7
c The 1. 5 x 10- g/ml dose of toxin by itself had no effect, and with
'

neostigmine (0. 25 mg) pretreatment it continued to show no effect.

d Atropine was used to assure that the preparation was respondin g
correctly.

When atropine was pr esent at 1. 0 x 10

-6

M the heart stop-

ped contracting.

e

.
-7
.
h
Atropine pres ent at 1. 0 x 10 M prutected against t e effect of

1. 0 x 10

-8

g/ml (5. 5 x 10

-8

M) acetylcholine.

f

Toxin given before acetylcho1.ine
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acetylcholine, and on numerous occasions checked with atropine as
an anticholinergic drug.

The data rn Table 1 show that the hearts

were all sensitive to acetylchol.ine at the concentration of 1. 0 x 10

-9

g/ml (5. 5 x l0- 9 M) and rnany of the hearts were sensitive to concen-13
-13
trations as low as 1. 0 x 10
g/ml (5. 5 x 10
M).

Table 1 contains

data that also show that when atropine was present at l. 0 x 10

-7

M

8

it protected the preparation against the effect of l. 0 x l0- g/ml

(5 •

r:
:J

8 . -)
·
.x 1.v., - Lvi
ac e t y l c b.o i ine.

from 1. 5 x JO
on the heart.

-18

At doses of the asterosaponin ranging

g/ml to 1. 5 x 10

-7

g/ml there was no effect produc ed

The adrninistration of neostigmine (0. 25 mg) to the

test preparat.i.on did not alter the lack of effect on the preparation
7
produced by l. 5 x 10- g/ml of asterosaponin.
B.

Effect of Asterosaponin on the Whole Clam

Mer~e~·ia_mer -

cena ria
Neither the asterosaponin injec tio n nor the sea water injection
into the intact clan1 caused any abnormal reac tio n by the cla:;:n.
Clams that were injected with 1. 0 ml of 1. 5 x 10

-4

g / ml of astero-

saponin did n ot appear to differ in any way fro1n the clan1 receiving

l. 0 ml of sea water.

Since many asterosaponins reviewed in the literature and sap onins in general exh ibjt hemolytic a ctivity it was detern.l.ined that
it \.Vould be nEcessary to evaluate this ::i.sterosaponin for l:ernolytic
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activity.

Table 2 shows that the astero saponin possessed no cytotoxic

activity towards rat l e ukocytes or erythrocytes at doses ranging
up to 10 mg/ml.
D.

A::itoto rn.e n d Asterosaponin
Since another investi gator (Cha et 1962) had sho wn th at an extract

from Asterias forbesi was c apab l e of inducing autotorny in
i£!be~i_,

Aste~ias

the asterosaponin was evaluated for autotor.-iy activity to

deterrnine if it was the active constituent.

The data (Table 3) denl.-

onstrate that the aste rosaponin from Asterias

forb c s_~ \.v as

able of causing autotomy in the starfish Asterias

incap-

.

f'.~ .:-:2~?.si.

The ability of thf:: asterosaponin to initiate an avoidance response
in Littorina littorea wa s evaluated (T a ble 4).
strate that wh::;n 1. 5 x 10

-5

The results demon-

g of asterosaponin was i nje c ted into the

water near the snails head no abnormal behavior was generated and
no avoidance r e sponse observed.
F.

Anti - inflammatory Acti v ity
Becaus e of the kno w n anti--inflammatory activity of a wide var1-

ety of steroids th e steroidal asterosaponin was tested for anti-infla1nmator y activity with two djfferent tests, the in vitE_£ bovine serum
albumin denaturati::rn as say and the in vivo carrageenin induced
rat bind paw edema a ssay.
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TABLE 2.

EVALU.A.TION OF BLOOD CELL LYSING

PROPE RTIES OF ASTEROSAPONIN

Treatment

Concentration

· - - --

,

a

Cytotoxic Activity
RBC
WBC

_Asterosap on in

10

no

no

Asierosap on in

5

no

no

Asterosaponin

2. 5

no

no

Asterosap o nin

1. 2

no

no

Asterosaponin

0.6

no

no

Asterosaponin

0. 3

no

no

yes

yes

Merck Saponin

a mg/ml of whole rat bl oo d

~ ·.
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TABLE 3.

AUTOTOMY BY ASTERIAS FORBESI IN RESPONSE
TO ASTEROSAPONIN INJECTION

T reatmenta

Nb

C oncentration

Asterosaponin

6

1. 5 x 10- 4 g/ml

Sea vVate r

2

100%

- - - - -·- -·- -a 1. 0 ml inj ection into the peritoneal cavity
b Number of starfish
c

Starfish were observed for 24 hours

Autotomy
no
no

c
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TABLE 4.

AVOIDANCE RESPONSE INITIATION

PROPERTIES OF ASTEROSAPONIN IN LITTORINA LITTOREA

T reatrnent

a

Asterosaponin
Sea '1'late r

Nb

Conc entration

10

.1. 5 x l0- 5 g/ml

3

Esca2e ResEonse

100%

a

1. 0 nl.l inj er:tion in irnmediate vicinity of the snails
b Number of animals

no
no
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The bovine serum album.in assay for anti-inflammatory activity
showed (Table 5) that a concentration of 500pg/ml of asterosaponin
caused an 85% inhibition of protein dena tu ration.

Phenylbutazone,

the well known anti-inflarnrna.tory agent, restricted the denaturat:ion by over 80% at a co:c.centration of l2Cpg/rnL

Vvhen the data

was plotted (Figure 2) both the aste rosaponin and phenylhutazone
produced this restriction of c!enaturation in a log dose response rnanSince the asterosap•Jnin ::-esuits were posib?c for this test

.w2r-.

which

is

used to screen new drugs for anti-inflar:nmato ry activity,

the in

viv~

carrageenin induced rat paw ederna as8ay was chosen

to deterrnine if the asteros2.;::;onin ·,;vas capable of r-=stricting in£lamn:cation in the intact aniinaL
The rat paw edema assay (Table 6) showed that pretreatment
with asterosaponin at 75 ing/kg ip reduced the ederna caused by the
carrageenin i1--;jection by 53 percent.

Pretreatrr1en t v; ith pbenylbut-

azone (90 mg/kg) had a sirnilar effect, decreasing inflarr1mation
by 52 p ercent.

The evaluation of the LD

50

of any toxic co.r:npound is pararno :rnt

to any type of drug tes t ing procedure.

1

The

d2. t ~,

of the LD ,- l.-, dete rm:::i

J

ination (Table 7) for the asterosaponin dern.onstrate that the aste.::-osaponin has a .L Dr.Ju,-, v::t lne ln mice between 100 and !.'.CO mg/kg
.
...
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TABLE 5.

ANTI-INFLAMMATORY ACTIVITY OF

ASTEROSAPONIN AND PHENYLBUTAZO NE THROUGH
THE BOVINE SERUM ALBUMIN ASSAY SYSTEM

T reatrnent

Aste ros a ponind
30
60
120
250
500
1000
Ph e nylbutazoned
30
60
120
250
500
1000
a

Percent of
Control Absorbancec

a

2
2
4
2
2
2

70. 34 ± 3.07
63. 63 ± 0. 00
55.06 +
- 2.84
28. 46 ± 4. 83
14. 31 +
- 3. 41
ll.92-!:0.79

2

53. 58
43. 32
17.49
0. 90
0. 90
0. 90

2

4
2
2
2

,ug /ml

b Nurnbe r of replicates
c

660 nm

d Significant drug effect P<O. 05 (Analysis o.f Va ria nce )

"±: 4. 22

+- 2. 23
+- 2.56
+
- 0.90

± 0. 90

+- 0.

90

100

w

(.)

z

FIGURE 2 . INHIBITION OF BOVINE SE RUM AL B UMIN
DE NA TURA TION BY AS T E ROSAPONIN A ND
P H E NYLBUT A ZONE
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TABLE 6.

b

a

Vohunec

Treatm_ent

N

Control

4

Asterosaponin
(75 mg/kg)

4

(. ~
14 oti.

Ph en ylbutazone
(90 mg/kg)

4

1476. 0

a

b
C

d

RAT PAW EDEMA

0 hr

1401. 1

~

103. 8

~.J::E. __ ____

(3 hr)-(0 hr)

+

800. 1 +
- 61. 5

2201. 2 - 143. 9

+ 28 • 5

1846. 3 -

+

70. 2

377. 7 ~ 81. 5d

~

1860. 4

~

88. 3

384.3~47.8d

oI -

72. l

Injection (ip) of test compound one hour prior to injection of 0. 05 ml of
car rageenin i'.1to tre sub planter tis sue of the hind paw

1%

Number of rats
.,

r

,

Vornrne or paw u1 mm

3

Si gnificantly lli.flerent from control, P<O. 05

>i'00
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TABLE 7.

Treatment

LD50 IN MICE FOR ASTEROSAPONIN

Dos ea

Nb

Aste rosaponin

400

5/5

Asterosaponin

200

5/5

Asterosapon i n

100

5/0

Aste :ros;:iponin

50

5/0

a
b

mg/kg, ip
Numb e r of rn.ice injected/numb e r <lead w ithin 48 hours
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H.

Analgesic Activity
In a further evaluation of pharrnacological activity, the anal-

gesic activity of the asterosaponin was evaluated, employing the
Koster acetic acid assay (Koster, 1959).

The asterosaponin was

effective in reducing the writhes exhibited by mice due bJ acetic
acid injection (Table 8) and therefore extremely effective as an analgesic agent.

VVi'..ile the 10 and 12 mg/kg doses did not reflect anal-

ger::ic activity, the 15 mg /kg dose did reduce the writhes exhibited

by the group by 71 percent.

Higher doses possessed even greater

analgesic activity as 25 mg/kg reduced thew rithes by 99 percent
and 50 mg/kg reduced w:rithes by 100 p e rcent.

These results of

asterosaponin incho_c.ed analgesia wel·e compared to the results ob tained with morphine which at 10 mg/kg reduced writhes by 100
percent.

I.

Cat Blood Pressure and Nervous Syst e m
The effects of aste ro saponin injected intrav eno usly at diffe cent

dosag es upon a number of physiological processes we re monitored
in the cat.

The effects of the toxin on blood pressure, respiration ,

prega nglionic sympathetic nerve stimulation, and stimulation of
a sornatic motor nerve to a striated muscle were all recorded .
Figure 3 shows the polygraph recordings that we r e taken of
a cat prior to any drug administration.

The char t shows an initial

blood pr essure of 100 mm Hg, ll, 5 breaths per minute, and the

51

TABLE 8.

MOUSE ANALGESIA AS EVALUATED FROM

WRITHES FOLLOWING ACETIC ACID INJECTIONS

Pretreatrn en t

a

S.::.line 0. 9%

Dose
-·

Trialsb

Writhesc

Percent of
Control

O.Olrn.1/g

4

146

1vfo rphine

10 mg/kg

2

0

0

Aste rosaponin

10 mg/kg

l

143

98

Aste ro saponin

12 mg/kg

l

139

95

Asterosaponin

15 mg/kg

1

43

29

Asterosaponin

20 mg/kg

1

11

7

Asterosaponin

25 mg/kg

1

2

1

Asterosap onin

50 mg/kg

1

0

0

a

b

ip injections 15 minutes prior to treatment with 0. 01 rng/g of
0. 6% acetic acid
Number of times that dose of compound was tested

c I\1ean nurnber of writhes exhibited by the group of 5 mice during
the 12 minute p erio d star.ting 3 rninute s aiter acetic acid injection

i.
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striated muscle contracting normally to stimulation.

The cont rac-

tion of the nictitating membrane is not shown but the membrane was
contractin g normally in response to nerve stimulation.
Figure 4 is a recording rnade after the intravenous injection
of l. 0 mg/kg of asterosaponin .

The blood pressure of the cat re-

mained at the pretreatment level of 100 mm Hg for 9 seconds and
then began to decline.

The lowest ievel of 50 mm Hg was reached

17 seconds after the injecti on .

The blood pressure returned to a

level of between 95 and 100 mm Hg 44 seconds after the injection.
The respiration, skeletal muscle contractions and nictitating membran e all functione d normally during the tim e that the drug was
active on the blood pres sure.
Figure 5 illustrates the e ffect of the injection of 2. 0 mg/kg
of asterosaponin on the monitored physiological functions of the
anesth etized cat.

The:re was the usual delay of onset of the act ion

of the asterosaponin, in this case 11 seconds, before there was a
drop in blood pressure.

Th e pressure reach ed its lowest level of

50 mm Hg 20 seconds after the injection, a drop of 42 mm Hg from
pre-drug level of 82 mm Hg.

The blood pressure did not return to

near normal l eve l for 126 seconds.

The nictitating membrane func-

tioned normally to the stimulus, but the contraction 0£ the skeletal
muscle, appeared to b e

sligh'~ly

decreased in arr1plitude .

pir ation was increas8d by this dose of ast:erosaponin<

The res-

The original

I
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respiratory rate was 11. 5 breaths per minute.

After the aste ro-

saponin the rate increased to 16 breaths per minute for approximately one minute then dropped to 15 per minute.

Nine minutes af-

ter asterosaponin injection resp.i.ration was still at an elevated level

0£ 14 breaths per minute although at this time the a ste ro sapo nin
had ceased to have an effect on the blood pressure.
The data for the response of the cat 1 s physiological para1neters
' for all of the do se s of asterosaponin adrninistered are compiled in
Table 9.

These data clearly show that the asterosaponin from As--

!erias forbesi was capable of dose dependentl y causing a transi ent
lowering of the blood pressure o f the anesthetized cat.

These data

also show that the asterosaponin had no eifect on autonomic ganglia
as the response 0£ the feline nictitating membrane was not altered
throughout the dose range administered when the preparation was
stimulated preganglionically.

The asterosaponin did not appreciably

affect the functioning of the somatic peroneal nerve or the functioning of the skeletal muscle.

J.

Rat Blood Pr essure , Heart Rate and ECG Response to Asterosaponii:
Figure 6 shows the norn1al recording for blood pr es sure and th

normal ECG pattern of a typical .r at before any drug vva.s injected.
The blood pressure was 75 mm Hg, there were 270 heart beats
per miP..ute and the ECG was r eg ular.

A control determination was
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TABLE 9.

EFFECT OF ASTEROSAPONIN ON CAT

Aste ro saponin

!:e-g /kg
0

Initial

Blood P ress ur e

a

Time b

100

Respiration

c

Muscle

11. 5

}.1axir:num
Eff ect

xi

H.eturn to
Nonnal
0.5 Initial
Max imum
Effect

70

19

Retu rn to
Normal

100

33

1. 0 Initial

x

100

Maximurn
Effect

50

17

Return to
Normd)_

95

44

2.0 Initial

a

100

82

x

11. 5

Maxi inum
Effect

40

20

16. 0

Return to
No rrnal

82

126

540e

mm Hg

og

d

b Tirne in seconds from inj ection of drug to maximal effect or for
return to pre-injection level.
c Breaths /min.
d Skeletal muscle response to nerve stin1ulation
.e

Seconds to full recovery

£ Norrnai TE;sp on se to i1erve stimulation
g Slight dee t·ea se in arnplitude
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made by the injection of 0 . 5 ml of 0, 9% saline into the rat through
the venous catheter to eva luate the effect of the injection procedure
itself.

A slight rise in the blood pressur e was noted within 8 seconds.

It rose fr om the 75 mrn Hg to a level of 82 rnm Hg in 20 seconds and
the heightened blood pressure l as ted for more then 90 seconds.
The heart rate was 280 beats per :minute during the tirne of activity
which vvas interpreted as being no t appreciably different from the
initial value.

The ECG did not change.

The intravenous injection of 1. 0 mg/kg of asterosaponin in the
rat resulted in a rise in blood pressure from 75 m .m Hg to 90 mm
Hg in 25 seconds.

Heart rate was 300 beats per minute, and the

shape of the ECG did not change.

The data in Table 10 show the

effects of 2 mg/kg of asterosaponin.

There was an initial drop in

the blood pres sure from 85 to 82 rnm Hg which lasted only eight
seconds and the pressure returned to about the norrnal level.

The

heart rat e just prior to injection and 40 seconds after administration
was 300 b e-'1 ts per minute, and the ECG pattern was not altered.
The adrn.inistration of 4. 0 mg/kg asterosaponin (Table 10) was
the lowest dose in the rat where unequivocal alterations in the rat
blood p ressure occured.

Thr ee to £our seconds after the drug was

administered there was a dr op in blood pressure from an initial
value 0£ 87 mm Hg to 70 rnm Hg in 18 seconds.

The blood pressure

was back to its normal value 35 seconds afte r drug adrninistration.
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TABLE 10.

RAT BLOOD PRESSURE AND ECG REACTIONS
TO ASTEROSAPONIN I.

Blood Pr es sure (mm Hg)

Aste ::_o sa p r~~in

a

foj

tia 1

After

0

75

0.5

75

82

l. 0

75

90

2. 0

85

82

4.0

87

8.0
20.0

Return to
Normalb

Heart Rate

Initial

d

+d
280

+

270

300

+

8

300

300

+

70

35

312

312

+

92

75

90

312

312

+

82

55

330

300

300

+

Time for :-eturn to pre-drug pr essure in seconds
Beats per minute

+ = no

ECG

270

90

Dos e iv in mg /kg

c

After

270

a

b

c

change in electrocardiograrn recording
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The heart rate was 312 beats per minute before and after drug administration and there was no change in the ECG.

For the 8. 0 and

20. 0 mg/kg (Figure 7) doses of asterosaponin the initial blood pressures were 92 and 82 mrn Hg respectively and the initial hearts
rates were 312 and 300 beats per minute (Table 10).
the drug at both doses was basically the same.

The effect of

After the drug was

administered there was an immediate drop in blood pressure which
lasted for 25 seconds, while the blood pressure did not completely
return to its normal value for minutes.

The heart rate and the ECG

were not affected.
The preceeding results for the effects of the asterosaponin
were obtained by evaluating only the asterosaponin extracted by
Les Goldsmith.

A similar experiment was performed to compare

the asterosaponin extracted by Les Goldsmith and the original extract supplied by Dr. Yuzuru Shimizu.

The base line blood pressure

was 90 mm Hg while the heart rate was 350 beats per minute.

The

effect on blood pressure and ECG of the standard 0. 5 ml saline injection was similar to that seen for the previous exp e rirnent.

The

heart rate ren1ained between 350 and 360 beats per 1ninute, while the
blood pressur e rose to a value of 97 mm Hg in 10 seconds.
Table 11 illustrate s the effects of the inj ectio n of 4. 0 mg/kg
C'.
_.
of the asterosaponin extracted by Dr. ._,n1m1zu.

These data show

that the initial blood pressure was 85 n1m. Hg a nd that th e h ea rt
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TABLE 11.

RAT BLOOD PRESSURE AND ECG REACTIONS
TO

ASTEROSAPOI'·JL~

Blood Pressure (mm Hg)

II.

Heart Rate

c

Initial

After

Return to
.
b
Normal

85

57

480

360

285

drop in
amplitude

10. 0 (S)

62

24

60

285

240

no change

4.0 (S)

85

57

400

360

285

irregular

10. 0 (S)

107

15

150

340

276

irregular

20.0 {G)

100

55

390

360

irregular

40.0 (G)

80

55

120

336

324

irregular

10. 0 (S)

70

27

85

306

288

drop in
amplitude

___
_,__
Asterosaoonin

a

4. O (S)cl

a

Initial

After

ECG

Dose iv in mg /kg

b Time for return to pre-drug pressure in seconds
c
d

.
Beats per minute
S rep re sen ts sample isolated by Shimizu, G repres e nts sample
isolated by Goldsmith
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rate was 360 beats per minute.

Four seconds after the aste ro saponin

administration a reduction in the blood pressure began.

Approximate-

ly 60 seconds aite r injection the lo\vest blood pres sure was reached,
a value of 57 mm Hg, which lasted for about five minutes.

The

blood pressure did not return to normal £or m .ore then eight minutes.
During these eight minutes the amplitude of the QRS complex of the
ECG was dee reased and the beats per minute decreased from 360
to a low of 285 beats per rninute.

Several replications were made

for the rat receiving 10 mg/kg 0£ asterosaponin (Table 11).
first 10 mg/kg injection was of Dr. Shimizu' s extract.

The

The heart

rate at the initiation 0£ the experiment was 285 beats per rninute,
the blood pressure was 62 mm Hg, and the ECG was normal.

Three

seconds after drug administration the blood pressure started to drop;
23 seconds aite r injection the pressure hit its lowest level of 24
mm Hg and the heart rate declined to 240 beats per minute.

The

effect only lasted one minute, and the rate and pressure returned to
the initial levels.

Similar alterations were seen following the ad-

ministration of another 10 mg/kg dose (Figure 8).

The blood pres-

sure before the inj e ction was 107 mm Hg and the heart rate was
340 beats p e r minute, with a normal ECG.

After the inj ection the

pressure plumm eted to 15 mn1 Hg in less than 25 seconds, ren1ain ed
at that level for two rn.inutes and then returr.ied to the 100 mn1 Hg
level after another 30 seconds.

Durin g this time the ECG became

'
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irregular; the amplitude increased and the form of the pattern changed into many strange and uninterpretable shapes.
dropped from the 340 to 276 beats per minute.

The heart rate

Figure 9 is the re-

cording of the effect of 20 mg/kg of the Les Goldsmith asterosaponin
which was ad1ninistered following the second injection and affect
of the 10 mg/kg 2.sterosaponin of Shirnizu.

The blood pressure pri or

to injection was 100 n1m Hg, aDd the heart rate was 340 beats per
Seven seconds after the intravenous adrn.inistration of the
asterosaponin, the blood pressure began to drop and 25 seconds
after the injection the pressure st2.bilized at 55 mm Hg and remained
at 55 mm Hg for inore then 3 minutes when the next dose of astero-saponin was administered.

Two minutes after the injection the blood

pressur e was still depressed (75 mm Hg).

The ECG had obvious

disturbances in its pattern, and th e heart rate was depressed.
K.

Aster osaponin and the Dog Blood Pressure and Heart Rate
Intravenous asterosaponin injections at various dosages were

evaluate d in the dog.

These data (Table 12) show that the dog was

sensitive to asterosaponin at a dose of 2. 0 mg/kg and that the dog
respond ed in the characteristic manner to the asterosaponin,

i.e.,

followin g the asterosaponin injection a drop in blood pressure was
seen which was only transient, and the response was dose depend e nt.
The drop 1n blood pressure was accompanied by an increase in pulse
pressure at all dosage l eve ls (Fi gure 10).

The increase rn pulse
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TABLE 12. EFFECTS OF ASTEROSAPONIN ON BLOOD PRESSURE
AND HEART RATE IN THE DOG

Prenaration
_,__._

a
b

c
d

e

Treatment

Dos e

a

Blood Pres sure
Before After

b

Pulse
c
Pressure

l

Aste rosaponin

2. 0

-160
100

-155
78

-60
77

1

Asterosaponin

3.0

180
90

162

90

70

2

Aste rosaponin

4.0

-175

2

Astero sap onin

10. 0

ti.S/ADd

Heart Ratee
Before A fte r

5/22

182

192

92

18/20

192

200

115

175
-105

-60
70

0 /10

225

232

5
-18
120

-160
88

-65
72

25/32

216

224

Dose iv in mg/kg
mm Hg:

Sys to lic/Diastolic

Pulse pre ssure b efo r e /Pulse pressur e after
Change in systolic pr e ssure/Change in diastolic pressure
Beats per minute

O'
00

'
t
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pressure was due to a disproportionate drop in the diastolic compared to the systolic pr e ssure, the diastolic pressure always decreased more then the systolic.

The heart rate of the dog was in-

creased slightly hy asterosaponin injection at all dosage levels.
L.

Vagal Influence on the Response of Rat Blood Pressur e and
Heart Rate to Asterosaponin
Vagal influence was not influential in the creation of the tran-

sient hypotension exhibited by rats following astero saponin administration as indicat e d by experiments performed on atropinized and
vagotomized rats.

Th e results (Table 13) indicate that asterosap-

onin at a dose of 5 mg/ kg was capable of reducing the blood pressure
in rats who had been previously treated with atropine at a sufficient
level, 0. 5 mg/kg to. suppress any vagal activity.

The results also

show that the a ste rosaponin was cap ab le of producing its effect when
both vagi we re s eve red.
M.

Hista1nine Releasing Pr operties of Asterosaponin in the Rat
The possibility that the as te rosaponin was reacting through

histamine release was investigated.

The data in Table 14 show that

when the antihistamine diphenhydramine wa s administered to a level
when exogenously administered h istamine no lon ge r produced its
hypotensive effects, aste rosaponin continued to exhibit its hypotensive action.

Histamine when injected at 0. 5 mg/kg created a direct

hypotensi on.

Jn this experi1nent a drop in pressure frorn 100 to SS
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TABLE 13.

RAT BLOOD PRESSURE AND HEART RATE;

VAGAL INFLUENCE IN THE ACTION OF ASTEROSAPONIN

Treatinent

Dose

a

c
Heart Rate
After
Initial

90

45

276

Left Vagus
~
d
Sti1nulation

75

70-90

300

Right Vagus
Stimulation d

100

7 5-115

75

60--75

402

414

75

75

414

390

75

75

390

390

Asterosaponin

Atropine
Left Vagus
Stimulation

25. 0

Blood Pressureb
Initial
After

0.5

Right Vagus
Stimulation

270

316

Asterosaponin

5.0

80

55

414

396

Cut Vagi
Asterosaponin

5. 0

77

55

384

396

a Dose iv in mg/kg
b

c
d

inm Hg
Beats per in1nute
Vagal stimula ti o n was 0. 01 volt s , 1. 0 Hz for 5 seconds
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TABLE 14.

HISTAMINE RELEASING PROPERTIES OF
A.STE ROSAPONIN IN THE RAT

Treatment

Diphenhyd ra1nine
Histamine

Initial

10. 0
0.5

Diphenhydramine
Histamine

10. 0
o. 5

Diphenhydramine
Asterosaponin

10. 0
15. 0

Blood Pres sur eb
After

6c
4
7
100------60------102------75
100

55

105--~---70--~---100-1~---60
60
60
75--~---50--~--- 75_12 ___ 40
40

5

a Dose iv in mg/kg
b

mm Hg

c Time in seconds until next extreme pressure was recorded

1-~-·

.......... _
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mm Hg was produced.

However, when the histamine was admin-

iste red to the diphenhyd ramine pretreated rat the blood pressure
did not drop.

On the other hand when 15 rng/kg of a ste ro saponin

was administered to the same rat that had received the same anti-histamine pretreatment , the asterosaponin (15 mg/kg) did produce
the characteristic transient hypotension decreasing the al ready
lowered blo oci pressure of 40 mm Hg down to 5 mm Hg.
N.

_A_~-~

Blocking_o r Beta

Stimu~ating

Properties of Aste rosap-

onin in the Rat
Asterosaponin produces a hypotensive effect when the alpha
receptors are bloc ked and when the beta receptors are blocked as
is shown in Table 15.

A rat was prepared for the usual blood pres-

sure, ECG evaluation including the venous catheter iza tion.

Phen-

oxybenzamine was then administered through the venous catheter
in doses of 0. 4 mg/kg until sufficient drug was present so that further doses no longer lowered blood pressure.
ed that alpha receptor activity was blocked.

It was then consider-

Asterosaponin inject-

ed at 15 mg/kg produced its transient hypotensive effect dropping
the already lowered blood pressure from 48 to 30 mm Hg.
In another rat the possible beta stimulating effect of asterosaponin was evaluated (Table 15).

When the rat was pr etreate d with

propranolol to the point where excess propranolol was present in
the animal and b eta receptor activity was blocked, asterosaponin

74

TABLE 15.

ALPHA BLOCKING AND BETA

S'T.IMULA TING EFFECTS OF ASTEROSAPONI N

Treatment

Dose a

52c

48

0.4
15. 0

48
48

48
30

0.9

78
70

25

Phe noxybenz.J.mine

0.4

Phenoxybenz arni ne
Asteros2.ponin
Propran olo l
Aste ro saponin

15. 0

a
b

b
Blood Pr essure
After
Initial

70-75

Dose iv in mg /k g
mm Hg

c Anirnal had already received phenoxybenz amin e to lower the
blood pres sure to this level

75

was intravenously administered at 15 mg/kg.

' The asterosaponin

produced a hypotensi ve effect, dropping the blood pres sure from
70 to 25 mm Hg.
0.

The Direct Effect of Asterosaponin on the Vasculature and the
Beta Stimulatin g Effect of A sterosaponin in the Rat - - The
Rat Hind Leg Perfusion
The pas sibility of the a ste rosaponin producing its hypotensive

response through some centrally mediated mechanism was evaluated
with the first rat hind leg perfusion preparation.

The preparation

also evaluated the ability of the aste rosaponin to produce hypotension
via direct action on the vasculature.

The data from Table 16 show

that the asterosaponin at a dose of 6. 25 mg/kg was capable of dilating the blood vessels of the rat hind leg upon inj e ctior.. and thus
increasing the flow of perfusate through that vascular system.
Spinal cord transection at the cervical level did not inhibit the vessel
dilating properties of the asterosaponin.
The data presented in Table 17 were from a hind leg perfusion
preparation that evaluated the reliability of the preparation, the
direct effect of asterosaponin on the vasculature, and the beta stimulating effect of the drug.

The injection of 4 pg of epinephrine,

a pred ominately alpha stimulant caused a constriction of the vasculature reflect e d by a drop in the rate of perfusat e flow.

Isoprc-

terenol (0. l mg iv) a pred ominate ly beta agonist, caused an incr ease
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TABLE 16.

EFFECTS OF ASTEROSAPONIN ON THE
PERFUSED RAT HIND LIMB I.

T reatrnent

Dose

Control
Asterosaponin

a

.
ing/kg

.qrop s /Minute

Percent of
Control

38
6.25

Transecti on of spinal cord
Asterosaponin

a

52

136

40
6.25

56

140

77

.'..

1

TABLE 17.

EFFECTS OF ASTEROSAPONIN ON THE

PERFUSED RAT HIND LIMB II.

Treatment

Amount
Injected

None

.,,,-:!<

Droes

a

Percent of Control
Rate of D roEs /Minute

167

Locke-Ringer

l ml

188

100

Epinephrine

4 ug

108

57

Locke-Ringer

l ml

160

100

Isoprote renal

0. 1 mg

184

115

180

100

136

75

172

100

None
Propranolol

0. l 1ng

None
Asterosaponin

15 mg

192

111

Locke-Ringer

1 rnl

180

100

Aste ro saponin

30 mg

216

120

168

100

152

90

152

100

216

142

None
Propranolol
Isoprote renal

0. 1 rr1g
0 .1 mg

:/~

;..,.:

None
Propranolol
Asterosaponin

0.1 mg
30 mg

a Drops per minute of perfusate passing through leg.
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in the flow of pe rfusate while the injection of l ml of perfusate solution had no effect on the flow.

Asterosaponin when injected at

15 or 30 mg iv dos e s into the preparation caused a substantial increase in the rate of p e rfusate flow.

The beta stimulating proper-

ties of the asterosaponin were eva luat ed with a two-fold experiment.
The preparation was pretreated with propanolol (0. 1 mg iv) a bet2.
blocker, and then injected with isoproterenol (0. 1 mg}.

The result

of the combination was a slight lowering of the flow of perfusate.
The animal was again pretreated with propranolol and then treated
with asterosapo nin (30. 0 mg}.

This time the flow of perfusate was

increased in response to the drug treatrn.e nt indicating that beta
blockade failed to alter asterosaponin effect.
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V.

A.

DISCUSSION

Properties Reported in the Literature
The evaluation of the pharmacological properties possessed

by the asterosaponin frcm Asterias forbesi was initiated by employing techniques that would test the compound for pharmacological
activities that had been demonstrated by other asterosaponins.
Why starfish contain complex asterosaponin corripounds has been
considered from the tin1e that the first asterosaponins were extracted (Yasumoto et al., 1964).

T he originaL researchers who worked

with the asterosaponins considered the possibility that the asterosaponins could be compounds used by the starfish to facilitate food
procur e ment via some toxic properties directed toward the starfish 1 s
prey, supposedly acting primarily on the adductor muscles of the
bivalves on which the starfish often feed (Aldrich, 1957; Nichols,

1964).

Some investigators even thought that if the compound was

toxic to starfish prey then it was possible that the prey species rnay
be sensitive to the compound an d react to it through some type of
avoidance response (Pratt and Campbell, 1956).

This avoidance

response reaction w as demonstrat ed for starfish extracts by Fange

(1963), Feder and Lasker (1964), and Mackie et al. (1968).
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The work of Friess et al. (1968) and Friess (1970) demonstrated that asterosaponin compounds from starfish did react with cholinergic systems .

His experiments showed that some asterosaponins

could inhibit the response to stimulation of the cholinergic rat phrenic
nerve-diaphram preparation.

It was expected then that the astero-

saponin from Asterias forbesi might possess some type of reaction
on cholinergic systems.

The clam heart bioassay (Florey, 1966)

was used to eva mate the cholinergic properties of the asterosaponin.
The heart of Mercenaria mercenaria was used in these experiments
to identify any toxic action by the asterosaponin that would give
the starfish any advantage in the predator--prey relationship.

The

data showed that the assay preparation was very sensitive to acetylcholine, reacting to concentrations as low as 5. 5 x l0-

13

M.

How-

ever, the asterosaponin had no cholinergic activity for the dose range
of 1. 5 x 10 -18 to l. 5 x 10 - 7 g I ml and that there were no abnormal
responses of the heart to the asterosaponin.

These data support

the contention that this asterosaponin from Asterias forb es i does
not offe r the starfish aid in opening the elam through an action on
the heart.

Other experiments, discussed below, varify that the

asterosaponin had n0 cholinergic a ctivity.
The investigation of th e toxicity of the ast e rosaponin to clam
tissues or the response oi mollusk ti ssu es to the asterosaponin
was continu e d with an investigab.on of th e effect of the asterosaponin

81

on the whole clam using experiments modeled after those of Lavoie

(1956) and Yasumoto et al. (1964) where holes were drilled into bivalve shells and the compound injected into the mantle cavity.

The

data from these experiments show that the asterosaponin did not
cause the clam to open and that the compound was not toxic to clams,
even at the high concentrations administered.

These results corres -

pond with th e work of Burnett (1955, 1960) who showed that Asterias
forbesi possess sufficient strength to open the bivalve without the
use of a toxin.
The possibility remained that even if the asterosaponin was
not toxic to the cla1n that prey species could be sensitive to the
compound and initiate an avoidance response to its pressence.
The experiments of Mackie et al. (1968) were used as a rnodel for
the experiments performed in this research to test this possibility.
The data from Table 4 show that the asterosaponin did not initiate
an avoidance response by Littorina littorea.
One of the important pharmacological prop erties reported for
the asterosaponins is their blood cell lysing capability (Rio

1963, 1965; Yasumoto et al. , 1964; Owellen

~t

al. , 197 3 ).

~al.

,

The work

of Rio et al. (1965) is interesting in that they examined asterosaponins from five differ e nt species of starfish, one of which was derived from Asterias forbesi, but is not b e lieved to be the same compound that was us ed in this in vestigation.

Rio reported h e molytic
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activity for four of the starfish species used but not for the asterosaponin from Asterias forbesi.

The results show that the astero-

saponin from Asterias forbesJ. used in this investigation was incapable of lysing either erythrocytes or leukocytes.
The aste rosaponin was moderately toxic to mice.

When var-

ious doses of asterosaponin were intraperitoneally injected into
mice the asterosaponin, was shown to produce 100 percent lethality
-wii:h a dose of 200 mg/kg.

These results show that the asterosap-

onin certainly had some pharmacological activity, even though it
had not demonstrated avoidance response activity, clam toxicity,
or hemolytic action.
B.

Activities of Asterosaponin not Previously Reported
The pharrnacological testing of the asterosaponin proceeded

into an investigation of the compound for activities not previously
reported to be present in asterosaponins.

The method of Koster

(1959) was used to evaluate the asterosaponin for analgesic activity.
The asterosaponin did, dose dependently, reduce the number of
writhes exhibited by a group of mice that had received an intraperitoneal injection of dilute acetic acid.

The presence of analgesic

properties on the part of a drug is subjective by definition, and thus
is difficult to confirm, but when a 25 mg/kg dose of asterosaponin
caused a reduction in the expression of irritation by 99 percent
it can at least b e said that there is a strong possibility that the
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asterosaponin ·is an analgesic.

There is no reference to analgesic

properties being exhibited or tested for by any of the other asterosaponins reviewed in the literature.
The initial test used to evaluate the anti-inflarnmatory capabilitie s of the aste rosaponin was the in vitro method of Grant et
al. (1970).

The Grant method evaluated the ability of a compound

to inhibit the heat denaturation of bovine serum albumin.

The abil-

ity oi a compound to inhibit the heat denaturation of protein may
not be a direct indicator of anti-inflammatory activity but compounds
~hat

are anti-inflammatory do exhibit this property

(Grant~~·,

1970; Mizushina and Kobayashi, 1968).
The data show that the asterosaponin inhibited the denaturation
of bovine serum albmnin as did phenylbutazone, and that the asterosaponin and phenylbutazone produced this inhibition of heat denaturation in a log dose response manner.

These results indicate that

the aste rosaponin has potential as an anti-inflammatory agent, and
further investigation into the anti-inflam1nato ry potentia 1 of the
, compound seemed desirable.
Following the positive results obtained for anti-inflarnmatory
activity for the asterosa.ponin with the bovine serum albumin assay,
a more stringent in vivo assay was used to evaluate the aste rosaponin.
The carrageenin induced rat hind paw edema assay of Winter was
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chosen for this purpose, (Winter et al., 1965) with the volume of
the paw being measured plethysmographically following the proce <lure of Van arman et al. (1965).

While it is not clear why anti-

inflammatory agents inhibit the denaturation of protein it is equally
obscure as to why the injection of carrageenin causes such marked
inflammation.

The carrageenin, which is a high molecular weight

polysacchari d,~

is derived from either of two algae Chondrus crispus

or

92:.g~rti n a

st_!::llata, and has been hypothesized to cre ate inflamma-

tion by many different means.

Crunkhorn and Meacock (1971) and

DiRosa (1972) concluded that it may be due to:

irritant properties,

the release of histamine, 5-hydroxytryptamine, or bradykinin,
prostaglan dins, and even reaction with the blood complement system_
as a

11

trigger 11 for non-immune inflammation.

Nevertheless, the

rat paw edema assay is a universally accepted method for the in
vivo evaluation of anti-inflammatory activity.

The assay results

showed (Tal>le .6) that both a stero saponin and phenylbutazone re stricted the edema formed as a result of carrageenin injection.

Ph enyl -

butazone ( 90 mg/kg) restricted th e edema by 5 2 percent and asterosaponin (7 5 mg /kg) restricted the edema by 53 percent.

The pos ·-

itive results of the bovine serum albmnin assay and these results
that show that the asterosaponin restricted the edema in rats to the
same extent as phenylbutazon e , establishes the asterosaponin from
l

Asterias forbesi as an anti-in£la1nmatory agent.

The combination
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of anti-inflammatory and analgesic activity is advantageous for
possible drug compounds.

Since the asterosaponin exhibits these

properties it is an excellent candidate for further evaluation, however the potent hypotensive properties of the compound could restrict
the use of the asterosaponin to certain specific situations.

Never-

theless the analgesic and anti-inflammatory properties of the asterosaponin are deserving of more investigation.
C.-

Cardiovascular Effects
The effect of asterosaponins on the mammalian cardiovascular

3ystem had not been investigated previously and the effects of the
asterosaponin on respiration, skeletal muscle contraction, and
autonomic nervous system functioning had only been studied using
the isolated rat phrenic nerve-diaphram preparation (Friess et al.,

1968; Friess, 1970).

The results obtained by Friess showed that

saponin extracts from both sea cucumbers and starfish inhibited
the response of the neuronally stimulated rat phrenic nerve-diaphram
preparation.

The rat phrenic nerve-diaphram preparation is chol-

inergic in nature and the destruction of its excitability by asterosaponin suggests anti-cholinergic activity.

The work of Friess in-

dicated that asterosaponins possess properties that are manifested
in mam1nalian systems, in contrast to the early work that was usually restricted to investigating the effects of starfish extracts on lower
species.

These studies showed that the asterosaponin did indeed
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exhibit true pharmacologic activity which could not be explained
by alluding to sirnple chemoreceptor sensitivity as could be done

Io r avoidance response reactions, or shell gaping activity.

The

property demonstrated by Friess however was a type of anti-choline rgic activity which is not demonstrated by the asterosaponin
from Asterias forbesi, as illustrated below.
The intravenous injection of the aste rosaponin from Aste rias
forbesi. caused significant results .

In the cat dosages of 0. 5 and

1. 0 mg/kg (Table 9) of the asterosaponin caused a sudden, evanescent drop in blood pressure with little or no effect on respiration ,
the contraction of the nictitating m e mbrane or skeletal muscle.
The 2. 0 r.ng/kg iv injecti on of asterosaponin created an even greater
drop in bl oo d pressure lasting much longer and caused an increase
in the respirat ory rate along with a sli g ht decrease in the amplitude

oi the contractions of the skeletal muscle.
saponin from

Ast~rias

Obviously the astero-

forbesi was not inhibiting the activity of th e

phrenic nerve of the cat, as the respiratory rate rose and certainly
the compound was not exerting any type of anticholinergic activity
as the cholin ergic fibers of the pe ro neal nerve innervating the tibialis ant e rior muscle were func.tioning almost normally.

The lack

of antich o lin ergic activity by the asterosaponin was also sho wn by
the dr op in blood p1·essure, if the compound we re exerting anticholin ergic activity the blood pressure would be expected to rise,
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as a result of the loss of parasympathetic control.

The compound

did not appear to have any effect on the ganglia or the functioning
of adrenergic nerves, as the responses to preganglionic stimulation
of the nictitating membrane were normal.

The hypotensive activity

of the asterosaponin was investigated in rats and dogs after these
effects were seen on the cat.

The experiments performed on rats

(Tables 10 and 11) and dogs (Table 12) show that the asterosaponin
could cause a transient hypotensive effect at low dosage, although
not as low as in the cat and that the extent of the hypotension and
the time which it lasted were both dose dependent.
No effect on heart rate or ECG in response to this asterosaponin injection were seen.

These data correspond with the lack of

activity the compound had demonstrated on the autonomic nervous
system of the cat and suggested that the hypot en sive activity seen
with the asterosaponin was not due to a depressor activity on the
heart.

In one rat the asterosaponin did appear to cause a depression

in the heart rate.

However, it is not believed that this was a direct

effect of the drug, but rather a product of a unique rat preparatio n,
or some type of a reflex.

This is believed because injections of

both the Goldsmith and Shimizu extracted asterosaponin into this
rat precipitat ed ECG irr egula rities and a dr op in heart rate.

On

all other occasions the asterosaponin did not effect the ECG or the
heart rate of the rat.

The iv inj ection of asterosaponin i nto the
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dog created dose dependent hypotension and an increase in the heart
rate, probably through a compensatory mechanism.

The hypotension

produced in the dog was unique in that the pulse pressure increased
as a result of asterosaponin administration.

Experiments performed

by Lederis and Medakovic (1974) with extracts of teleost fish produced similar results in the rat.

In the experiments by Lederis and

Medakovic pulse pressure was increased following the administration
of drug and the increase was due to a more extensive drop in dias tolic pressure then in systolic pressure.
j_ndicated dilation of

resistanc~

vessels.

They concluded that this
Siinilar results were ob-

tained with the dog preparation subjected to asterosaponin injections.
At all dosages of asterosaponin the pulse pressure increased due
to a greater depression in diastolic rather than systolic pressure,
implicating some type of vasodilai:ion as being produced by the
asterosaponin.

Lederis and Medakovic also observed a reflex m-

crease in heart rate due to the hypotension caused by the teleost
extract.

The results of the dog heart rate and blood pressure ex-

periments indicated that the asterosaponin rn.ight have created its
hypotensive effect via a direct action on the vasculature .

The pro-

duction of hypot e nsion by the asterosaponin by working directly on
the vasculature would also explain the effects of the asterosaponin
on the respirat o ry rate of the cat.

Schoop

e t~·

(1957) demonstrate d
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that the hypotension produced by nitroglycerine caused a reflex
hyperpnea in the rat.

Thus if the asterosaponin was causing dir e ct

vasodilation the respiratory stimuiation might be explained.
The transient hypotensive effect of asterosaponin injection was
further investigated as to the mechanism of its action.

The expe r -

iments performed on the cat and dogs had not sufficiently established how the asterosaponin was creating its effe.:::t so fur·ther experim.ents \Vere performed on rats whose blood pressure and ECG were
monitored, under a variety of conditions.
The possibility of the asterosaponin creating hypotension through
vagal stimulation was investigated by testing the effect oi asterosap-.
onin on atropinized and vagotornized rats (Table 13).

These results

show that the asterosaponin continued to exhibit its hypot en sive
effect even when the vagus nerves were sever e d.

These results in

ccnjunction with the results from the cat experi1nent that showed no
cholinergic activity, and the negative results gained with the cla1n
heart assay for cholinergic activity, discount the possibility 0£ the
ast erosaponin from Asteria_::; forbesi acting through vagal stimulation.
The asterosaponin was examined £or histamine releasing properties in rats (Table 14).

These data shovv· that antihistamine pre-

treatment did not interfere with a ste ro saponjn-induced hypo tension..
These resul ts correspond with the anti-inflamrn.atory activity of
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the asterosaponin so that it can be conclud ed that the hypotensive
action of the asterosaponin is not due to endogenous histamine
release.
The data from the cat and dog blood pres sure experiments
indicate that the aste rosaponin worked directly on the vasculature.
The lack of effect exhibited by the asterosaponin on the cat nictitating rn.ernbrane preparation indicated that the drug was not acting
through the autonomic nervous system.

The possibility that the

hypotensive action was due to alpha adrenergic blockade or beta
2drenergic stimulation was further evaluated with the rat blood pressure and hind leg exp eriments .

The experiments performed on rat

Blood pressure and ECG (Table 15) established that the asterosap-·
onin was fully capable of eliciting its characteristic hypotensive
response when the alpha or beta receptors were blocked.

These

results thus add strength to the contention that the asterosaponin
is not an alpha blocker or a beta stimulant.
The rat hind l eg perfusion preparation supplied much needed
information on the mechanism of action of the asterosaponin.

The

first hind leg perfusiun preparation (Table 16) established that the
asterosapoGin was not acting through any centrally rnedjated process
by showjng that

t~e:

asterosaponin continued to be effective as a

hypotensive agent even after cer v ical tr-an section.

Th e second

preparation (Table 17) showed that the asterosaponin was not acting
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through beta stimulation, and together with the data obtained from
the rat alpha blockade and beta stimulation experiments produced
enough evidence to establish that the aste rosaponin was not acting
through any adrene rgic mechanism.

The. data obtained frorn the

hind leg perfusion experiments, along with all the other data produced i.D the inv e stigation of the aste rosaponin' s activity establish
that the aster o saponin from Asterias forbesi created its hypotensive
effects thrcugh direct action on the vasculature.
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VI.

1.

SUMMARY AND CONCLUSIONS

The asterosaponin extracted from the Atlantic starfish Asterias
forbesi exhibited no cholinergic activity towards the Mercenaria
mercenaria heart bioassay for acetylcholine at concentrations
ranging from 1. 5 x 10 -18 g I ml (1. 0 x 10 -18 M) to 1. 5 x 10 -7 g I ml
(l. 0 x 10

2.

-7

M).

The aste rosaponin produced no observable e££ects on the whole
clam Merc enaria rnercenaria when a dose of l. 5 x 10- 4 g/ml
was injected into the mantle cavity.

3.

No blood ceil lysing activity was exhibited by the asterosaponin
when tested from O. 3 mg /ml to 10. 0 mg /ml.

4.

The asterosaponin produced no autotomy in Asterias forbesi
4
at a concentr ation of l. 5 x l0- g/ml when injected into the
peritoneal cavity.

5.

No escape response was elicited in Littorina littorea by astero5
saponin when 1 ml of 1. 5 x l0- g/ml was injected near the head
of the snail that was in a dish of sea water.

These results

along with the results of the clam heart bioassay, and the whole
clam assay indicate that the asterosaponin is probably not used
by the starfish to facilitate prey procurement.
6.

The asterosaponin inhibited the heat denaturation of l percent
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bovine serum albumin by 89 percent when added to the incubation
medium at a concentration of 1000 pg/ml.

This inhibition of

denaturation was dose dependent and suggestive of possible
anti-inflamma tory activity.

7.

The asterosaponin at 75 m.g/kg inhibited rat paw edema formation
due to subplanter injection of carrageenin by 53 percent.
results of the

i~

The

vitro_ bovine serum albumin assay and those

of the in ;:i.Yo carrageenin induced hind paw edema assay establish the asterosaponin as an anti-inflammatory agent.
3.

The LD 50 of the asterosaponin to mice was between 100 and
200 mg/kg.

9.

The blood pressure of the c at dropped in response to 0. 5 mg/kg
of the intravenously administered asterosaponin.

The respi-

ratory rate rose and the blood pressure fell in response to

2. 0 m .g /kg of the asterosaponin, but there wa s no effect en the
preganglion ic stimulation of the nictitating membrane and littl e
effect on the neuronal stimulation of ske letal muscle at the

2. 0 mg/kg l evel.
10.

Transient, dose dependent hypotension was produced in rats
administered asterosaponin (4. 0 to 20. 0 mg/kg).

The heart

rate and ECG were not appreciably directly affected by the
compound.
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11.

The iv administration of asterosaponin (2. 0 to 10. 0 mg/kg)
caused transient hypotension in the dog.

This hypotension was

indicative of va sodilation as the pulse pressure rose because
of a greater drop in diastolic rather than systolic pressure.
Heart rate rose following asterosaponin induced hypotension
probably as a compensatory mechanism.

12.

In the rat, the asterosaponin (5. 0 mg/kg) caused hypotension
even afte1· tre yagus nerves were severed.

This along with the

lack of cholinergic activity exhibited by the clam heart bioassay
for acetylcholine, the lack of effect the asterosaponin exhibited
on the neuronaily stinrnlated skeletal muscle of the cat, and the
increase in respiratory rate of the cat established that the
asterosaponin was not causing hypotension through vagal stimulation or cholinergic activity .

13.

The asterosaponin (15 mg/kg) continued to exhibit its characteristic evanescent hypotension following antihistamine (diphenhydramine 10 mg /kg) pretreatment.

This indicated that the

asterosaponin did not produce hypotension through endogenous
histamine r e lease.

These conclusions were supported by the

anti-inilarnmatory properties oi the asterosaponin .

14.

The aste r osaponin's (15 mg/kg) hypotensive properties rn the
rat were not stopped by alpha adrenergic blockade by phenoxyb enzan1ine (0. 4 mg/kg).

These results along with the lack of
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activity the asterosaponin had on the nictitating membrane of
the cat established that the asterosaponin was not causing hypotension th.rough alpha blockade.
15.

When the aste rosap oni n (15 mg/kg) was injected iv into the rats
pretreated with the beta adrenergic blocking agent propranol o l
(0. 9 mg/kg), the hypotensive activity was still present, indieating th ac the as te rosaponin was not a beta stimulator.

The

absence of beta-stimulating properties by the asterosaponin
was further established by the results of the rat hind leg perfusion experiments, where 30 mg of asterosaponin was effective in creating hypotension after established beta blockade.
16.

The fa.ct th.at the asterosaponin was not causing hypotension
through any cenLally mediat e d process was established when
cervical t r ansection of the hind leg perfusion preparation failed to diminish the asterosaponin (6. 25 mg) induced vasodilation.
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